Piper Sandler Maintains Neutral on Pacific Biosciences, Raises Price Target to $2
Benzinga Newsdesk 12 months ago
NewsPrice TargetAnalyst Ratings
Piper Sandler analyst David Westenberg maintains Pacific Biosciences (NASDAQ:PACB) with a Neutral and raises the price target from $1.5 to $2.
Piper Sandler analyst David Westenberg maintains Pacific Biosciences (NASDAQ:PACB) with a Neutral and raises the price target from $1.5 to $2.